Open Label Adaptive Design Study To Evaluate D1 Receptor Occupancy (ro) Following Single Dose Of Pf-06412562, Using Positron Emission Tomography (Pet) With Ligand [11c]sch23390 In Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2014
At a glance
- Drugs PF 6412562 (Primary)
- Indications Cognition disorders; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Pfizer
- 23 Nov 2014 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 28 Oct 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
- 05 Oct 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015, as per ClinicalTrials.gov record.